Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/07/26	US$0.9660	-1.04%	207,596
16/07/26	US$0.9762	-8.77%	121,296
15/07/26	US$1.070	+9.13%	269,237
14/07/26	US$0.9805	-0.31%	174,362
13/07/26	US$0.9835	+1.08%	450,718

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9660USD

Average target price

11.00USD

Spread / Average Target

+1,038.72%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2026 BST			5-day change	1st Jan Change
0.9660 ^USD	-1.04%		-0.72%	-66.34%

07-15	Tempest Therapeutics Unveils Next-Generation In Vivo CAR-T Pipeline With First Clinical Study Planned For The Fourth Quarter Of 2026	CI
06-29	Rani Therapeutics Names Nicholas Maestas CFO	MT

Market Cap	14.3M 12.5M 11.53M 10.63M 20.04M 1.38B 20.48M 138M 54.23M 675M 53.72M 52.54M 2.32B	P/E 2026 *	-0.72x	P/E 2027 *	-0.8x
Enterprise Value	14.3M 12.5M 11.53M 10.63M 20.04M 1.38B 20.48M 138M 54.23M 675M 53.72M 52.54M 2.32B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	68.22%	Yield 2026 *	-	Yield 2027 *	-

07-15	Tempest Therapeutics Unveils Next-Generation In Vivo CAR-T Pipeline With First Clinical Study Planned For The Fourth Quarter Of 2026	CI
06-29	Rani Therapeutics Names Nicholas Maestas CFO	MT
06-26	Tempest Therapeutics Registers 2.43 Million Shares for Resale	MT
06-05	Tempest Therapeutics CFO Nicholas Maestas Resigns	MT
06-04	Tempest Therapeutics, Inc. Announces Directorate Appointments, Effective June 4, 2026	CI
06-04	Tempest Therapeutics, Inc. Announces Resignation of Nicholas Maestas as Chief Financial Officer, Effective June 5, 2026	CI
06-04	Tempest Therapeutics, Inc. Announces Executive Changes, Effective June 5, 2026	CI
05-29	Tempest Therapeutics, Inc. Announces Resignation of Simantov from Director Role, Effective May 23, 2026	CI
05-22	Tempest Therapeutics, Inc. Announces Board Resignations, Effective May 22, 2026	CI
05-14	Tempest Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-06	Tempest Therapeutics, Inc. Presents Clinical Update For TPST-2003 Dual-Targeting CAR-T Therapy	CI
04-14	Tempest Therapeutics, Inc. Appoints Andrew Fang, Ph.D. as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts	CI
04-03	Tempest Therapeutics, Inc. announced that it has received $1.999539 million in funding from Factor Bioscience Inc. and other investors	CI

01-22	HC Wainwright Upgrades Tempest Therapeutics to Buy From Neutral, Price Target is $11	MT
10/04/25	HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy	MT
14/03/24	Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	MT
11/10/23	HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating	MT
23/03/23	Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating	MT

Tempest Therapeutics, Inc. Share Price

Stocks

TPST

US87978U2078

Biotechnology & Medical Research

Valuation: Tempest Therapeutics, Inc.

Chart: Tempest Therapeutics, Inc.

Latest news : Tempest Therapeutics, Inc.

Analysts' recommendations: Tempest Therapeutics, Inc.

Press Releases: Tempest Therapeutics, Inc.

News in other languages: Tempest Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Tempest Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-15	Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026	AQ
06-04	Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors	AQ
05-29	Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds	AQ
05-14	Tempest Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
05-06	Tempest Presents Clinical Update at ISCT 2026 Annual Meeting	AQ

1 day	-1.04%
1 week	-0.72%
Current month	-12.97%
1 month	-21.46%
3 months	-50.71%
6 months	-64.49%
Current year	-66.34%

1 week	0.93	1.09
1 month	0.93	1.31
Current year	0.93	3.15
1 year	0.93	12.23
3 years	0.93	127.01
5 years	0.93	238.16
10 years	0.93	533

Manager	Title	Age	Since
Andrew Fang PRN	Corporate Officer/Principal	-	13/04/2026
Matthew Angel CEO	Chief Executive Officer	45	02/02/2026
Justin Trojanowski DFI	Director of Finance/CFO	37	04/06/2026

Director	Title	Age	Since
Mike Raab CHM	Chairman	61	31/12/2020
Stephen Brady CHM	Chairman	56	02/02/2026
Christine Pellizzari BRD	Director/Board Member	58	30/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
04/06/26	William Richey	Other	Director	2,000	0.0148%
04/06/26	John Yee	Free	Director	25,000	0.1854%
04/06/26	William Richey	Free	Director	25,000	0.1854%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TEMPEST THERAPEUTICS, INC.	-1.04%	-0.72%	-84.65%	-93.24%	14.3M
LONZA GROUP AG	-0.55%	-3.67%	+0.96%	+2.64%	49.18B
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+386.06%	+588.97%	39.58B
BEONE MEDICINES AG	-1.70%	+4.46%	+5.93%	+61.54%	34.69B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+28.41%	-8.52%	34.42B
CELLTRION, INC.	+0.06%	+0.34%	+2.38%	+34.47%	27.11B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.21B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+72.42%	+116.45%	15.36B
EUROFINS SCIENTIFIC SE	+0.88%	+2.01%	+15.13%	+17.93%	14.05B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+18.43%	-31.23%	13.02B
Average	+0.31%	-0.05%	+49.45%	+76.56%	24.36B
Weighted average by Cap.	+0.53%	-0.18%	+79.75%	+122.45%

	2026 *	2027 *
Net sales	-	-
Net income	-19.9M -17.39M -16.05M -14.79M -27.88M -1.92B -28.5M -192M -75.44M -939M -74.73M -73.09M -3.23B	-21.9M -19.14M -17.66M -16.28M -30.68M -2.11B -31.36M -211M -83.03M -1.03B -82.25M -80.44M -3.56B
Net Debt	-	-